Read about our research in our publications:

‘Novel cell based in-vitro screen to identify small molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophages’, Samantaray S, Correia JN, Garelnabi M, Voelz K, May RC, Hall RA, Journal of Antimicrobial Agents, July 2016, Volume 48, Issue 1, pp69-77.

Cryptococcus neoformans thermotolerance to avian body temperature is sufficient for extracellular growth but not intracellular survival in macrophages’, Johnston SA, Voelz K, May RC, 2016, Sci. Rep. 6, 20977.

What makes Cryptococcus gattii a pathogen?’, Bielska E, May RC, FEMS Yeast RES, 2016 Feb: 16(1)

‘“Division of labour” in response to host oxidative burst drives a fatal Cryptococcus gattii outbreak’, Voelz K, Johnston SA, Smith L, Hall R, Idnurm A, May RC, Nature Communications, 2014, 5:5194.

Cryptococcal Phospholipase B1 is required for intracellular proliferation and control of titan cell morphology during macrophage infection’, Evans RJ, Li Z, Hughes WS, Djordjevic JT, Nielsen K, May RC, Infection & Immunity, 83:1296-1304 (2015).

The fungal pathogen Cryptococcus neoformans manipulates macrophage phagosome maturation’, Smith LM, Dixon EF, May RC, Cellular Microbiology, (2014).

Genotypic diversity is associated with clinical outcome and phenotype in cryptococcal meningitis across Southern Africa’, Beale MA et al.  PLoS Negl Trop DIs 9, e0003847 (2015).

‘Genome evolution and innovation across the four major lineages of Cryptococcus gattii’ , Farrer RA, Desjardins CA, Sakthikumar S, Gujja S, Saif S, Zeng Q, Cheng Y, Voelz K, Heitman J, May RC, Fisher MC, Cuomo CA, mBio., 2015 Sep-Oct; 6 (5): e00868-15.

  Home    About Mitofun     Meet the Team     News & Events     Publications     Contact Us     Links

This project is funded by the European Research Council under the European Union’s Framework 7 Programme (FP/2007-2013)/ERC Grant Agreement No. 614562